This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2006 May 27;332(7552):1266-8.

doi: 10.1136/bmj.332.7552.1266.

Review of NICE's recommendations, 1999-2005

James Raftery¹

Affiliations

PMID: 16735341
PMCID: PMC1471962
DOI: 10.1136/bmj.332.7552.1266

Review

Review of NICE's recommendations, 1999-2005

James Raftery. BMJ. 2006.

. 2006 May 27;332(7552):1266-8.

doi: 10.1136/bmj.332.7552.1266.

Author

James Raftery¹

Affiliation

¹ Wessex Institute of Health Research and Development, University of Southampton, Southampton SO16 7PX. j.p.raftery@soton.ac.uk

PMID: 16735341
PMCID: PMC1471962
DOI: 10.1136/bmj.332.7552.1266

Erratum in

BMJ. 2006 Jul 15;333(7559):137

No abstract available

PubMed Disclaimer

Figures

Figure 1
Yes but Credit: AKG IMAGES

See this image and copyright information in PMC

Comment in

How NICE may be outflanked.
Ferner RE, McDowell SE. Ferner RE, et al. BMJ. 2006 May 27;332(7552):1268-71. doi: 10.1136/bmj.332.7552.1268. BMJ. 2006. PMID: 16735342 Free PMC article. Review. No abstract available.
NICE work: nice try.
Shuster S. Shuster S. BMJ. 2006 Jun 10;332(7554):1394. doi: 10.1136/bmj.332.7554.1394. BMJ. 2006. PMID: 16763270 Free PMC article. No abstract available.

Similar articles

Prognosis without treatment as a modifier in health economic assessments.
Camidge R, Walker A, Oliver JJ, Nussey F, Maxwell S, Jodrell D, Webb DJ. Camidge R, et al. BMJ. 2005 Jun 11;330(7504):1382-4. doi: 10.1136/bmj.330.7504.1382. BMJ. 2005. PMID: 15947403 Free PMC article. Review.
Crossing the line: NICE's value for money threshold.
Appleby J. Appleby J. BMJ. 2016 Mar 9;352:i1336. doi: 10.1136/bmj.i1336. BMJ. 2016. PMID: 26960807 No abstract available.
The "real-life" death panel, reformed.
Latham SR. Latham SR. Hastings Cent Rep. 2011 Jan-Feb;41(1):1 p following 52. Hastings Cent Rep. 2011. PMID: 21329106 No abstract available.
How NICE may be outflanked.
Ferner RE, McDowell SE. Ferner RE, et al. BMJ. 2006 May 27;332(7552):1268-71. doi: 10.1136/bmj.332.7552.1268. BMJ. 2006. PMID: 16735342 Free PMC article. Review. No abstract available.
Should NICE's threshold range for cost per QALY be raised? No.
Raftery J. Raftery J. BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185. BMJ. 2009. PMID: 19171562 No abstract available.

See all similar articles

Cited by

Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research.
Chalkidou K, Hoy A, Littlejohns P. Chalkidou K, et al. J R Soc Med. 2007 Oct;100(10):453-60. doi: 10.1177/014107680710001013. J R Soc Med. 2007. PMID: 17911127 Free PMC article. No abstract available.
Use of economic evaluation in decision making: evidence and recommendations for improvement.
Simoens S. Simoens S. Drugs. 2010 Oct 22;70(15):1917-26. doi: 10.2165/11538120-000000000-00000. Drugs. 2010. PMID: 20883050
Valorising and creating access to innovative medicines in the European union.
Annemans L, Cleemput I, Hulstaert F, Simoens S. Annemans L, et al. Front Pharmacol. 2011 Oct 11;2:57. doi: 10.3389/fphar.2011.00057. eCollection 2011. Front Pharmacol. 2011. PMID: 22013421 Free PMC article.
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Paz-Ares L, García del Muro X, Grande E, González P, Brosa M, Díaz S. Paz-Ares L, et al. Clin Transl Oncol. 2008 Dec;10(12):831-9. doi: 10.1007/s12094-008-0297-3. Clin Transl Oncol. 2008. PMID: 19068454 Clinical Trial.
Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?
Barton GR, Sach TH, Jenkinson C, Avery AJ, Doherty M, Muir KR. Barton GR, et al. Health Qual Life Outcomes. 2008 Jul 14;6:51. doi: 10.1186/1477-7525-6-51. Health Qual Life Outcomes. 2008. PMID: 18625052 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Ham C, Robert G. Conclusions. In: Reasonable rationing. International experience of priority setting in health care. Milton Keynes: Open University Press, 2003: 141-56.
1. Duckett SJ. Drug policy down under: Australia's pharmaceutical benefits scheme. Health Care Financing Review 2004;25(3): 55-67. - PMC - PubMed
1. Porter RJ, Mulder RT. PHARMAC and availability of pharmaceuticals. N Z Med 2002;115: 274-5. - PubMed
1. Corvari R, King D, Sanidas M. Canada: pharmaceutical pricing and reimbursement. London: London School of Economics, 2005.
1. Stiftung B. Centre for quality in medicine: from policy paper to draft bill. Westphalia: Health Policy Monitor, 2004.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources